Loading...
Loading...
AVIR| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 40.8M |
| Operating I/L | -40.8M |
| Other Income/Expense | 7.9M |
| Interest Income | 7.9M |
| Pretax | -32.9M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -33.1M |
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of antiviral therapeutics. The company's lead product candidate, AT-527, is in Phase II clinical trial for the treatment of COVID-19. Atea also develops AT-752, AT-777, AT-787, and AT-281 for the treatment of various viral infections, including dengue, yellow fever, Zika virus, and coronaviridae viral infection. Additionally, the company has a license agreement with Merck & Co, Inc. for the development and commercialization of ruzasvir, an oral NS5A inhibitor for the treatment of chronic HCV infection.
